BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 25452438)

  • 21. Olaparib: first global approval.
    Deeks ED
    Drugs; 2015 Feb; 75(2):231-40. PubMed ID: 25616434
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in
    Mateo J; de Bono JS; Fizazi K; Saad F; Shore N; Sandhu S; Chi KN; Agarwal N; Olmos D; Thiery-Vuillemin A; Özgüroğlu M; Mehra N; Matsubara N; Young Joung J; Padua C; Korbenfeld E; Kang J; Marshall H; Lai Z; Barnicle A; Poehlein C; Lukashchuk N; Hussain M
    J Clin Oncol; 2024 Feb; 42(5):571-583. PubMed ID: 37963304
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Olaparib and pancreatic cancer: A challenging Lesson].
    Louvet C; Samalin E; Michel P
    Bull Cancer; 2019 Sep; 106(9):715-716. PubMed ID: 31399206
    [No Abstract]   [Full Text] [Related]  

  • 24. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
    Gelmon KA; Tischkowitz M; Mackay H; Swenerton K; Robidoux A; Tonkin K; Hirte H; Huntsman D; Clemons M; Gilks B; Yerushalmi R; Macpherson E; Carmichael J; Oza A
    Lancet Oncol; 2011 Sep; 12(9):852-61. PubMed ID: 21862407
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Case of Recurrent Breast Cancer with BRCA2 Mutation Successfully Treated with Olaparib Therapy].
    Yoneda H; Shimizu Y; Masuda R
    Gan To Kagaku Ryoho; 2020 May; 47(5):815-818. PubMed ID: 32408326
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The evolution of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer.
    Domchek SM
    Clin Adv Hematol Oncol; 2018 May; 16(5):330-332. PubMed ID: 29851928
    [No Abstract]   [Full Text] [Related]  

  • 27. Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline
    Lundy J; McKay O; Croagh D; Ganju V
    JCO Precis Oncol; 2022 Jan; 6():e2100437. PubMed ID: 35085003
    [No Abstract]   [Full Text] [Related]  

  • 28. Olaparib effective in four advanced cancers.
    Cancer Discov; 2015 Jan; 5(1):OF3. PubMed ID: 25583815
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Olaparib Keeps Hereditary Breast Tumors in Check.
    Cancer Discov; 2017 Aug; 7(8):OF10. PubMed ID: 28583909
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients.
    Capoluongo E; Ellison G; López-Guerrero JA; Penault-Llorca F; Ligtenberg MJL; Banerjee S; Singer C; Friedman E; Markiefka B; Schirmacher P; Büttner R; van Asperen CJ; Ray-Coquard I; Endris V; Kamel-Reid S; Percival N; Bryce J; Röthlisberger B; Soong R; de Castro DG
    Semin Oncol; 2017 Jun; 44(3):187-197. PubMed ID: 29248130
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Defective DNA repair mechanisms in prostate cancer: impact of olaparib.
    De Felice F; Tombolini V; Marampon F; Musella A; Marchetti C
    Drug Des Devel Ther; 2017; 11():547-552. PubMed ID: 28280302
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Population Frequency of Germline BRCA1/2 Mutations.
    Maxwell KN; Domchek SM; Nathanson KL; Robson ME
    J Clin Oncol; 2016 Dec; 34(34):4183-4185. PubMed ID: 27551127
    [No Abstract]   [Full Text] [Related]  

  • 33. PARP inhibitors plough on.
    Mullard A
    Nat Rev Drug Discov; 2017 Mar; 16(4):229. PubMed ID: 28356598
    [No Abstract]   [Full Text] [Related]  

  • 34. [Hereditary ovarian carcinomas: clinico-biological features and treatment].
    Floquet A; Stoeckle E; Croce S; Longy M; Mc Grogan G; Barouk E; Bubien V; Garbay D; Joly E; Guyon F
    Bull Cancer; 2014 Feb; 101(2):167-74. PubMed ID: 24555961
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PARP inhibitors for chemoprevention--reply.
    To C; Sporn MB; Liby KT
    Cancer Prev Res (Phila); 2014 Nov; 7(11):1172. PubMed ID: 25368012
    [No Abstract]   [Full Text] [Related]  

  • 36. PARP inhibitors for chemoprevention--letter.
    Chand SN; Blanco FF; Jimbo M; Tsangaris TN; Cristofanilli M; Yeo CJ; Winter JM; Pishvaian MJ; Brody JR
    Cancer Prev Res (Phila); 2014 Nov; 7(11):1170-1. PubMed ID: 25368011
    [No Abstract]   [Full Text] [Related]  

  • 37. OlympiAD trial: moving to a next level of treatment for patients with BRCA mutation and her2-negative metastatic breast cancer.
    Sanchez AM; Orlandi A; Franceschini G; De Lauretis F; Terribile D; Franco A; Masetti R
    Ann Palliat Med; 2020 Mar; 9(2):510-511. PubMed ID: 32075400
    [No Abstract]   [Full Text] [Related]  

  • 38. A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.
    Schouten PC; Dackus GM; Marchetti S; van Tinteren H; Sonke GS; Schellens JH; Linn SC
    Trials; 2016 Jun; 17(1):293. PubMed ID: 27323902
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PARP inhibitors: targeting the right patients.
    Azvolinsky A
    J Natl Cancer Inst; 2012 Dec; 104(24):1851-2. PubMed ID: 23231976
    [No Abstract]   [Full Text] [Related]  

  • 40. Long-Term Responders on Olaparib Maintenance in High-Grade Serous Ovarian Cancer: Clinical and Molecular Characterization.
    Lheureux S; Lai Z; Dougherty BA; Runswick S; Hodgson DR; Timms KM; Lanchbury JS; Kaye S; Gourley C; Bowtell D; Kohn EC; Scott C; Matulonis U; Panzarella T; Karakasis K; Burnier JV; Gilks CB; O'Connor MJ; Robertson JD; Ledermann J; Barrett JC; Ho TW; Oza AM
    Clin Cancer Res; 2017 Aug; 23(15):4086-4094. PubMed ID: 28223274
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.